Hormone replacement therapy and endometrial cancer risk: A meta-analysis

20 Feb 1995MD, MPH Deborah Grady, MPH Tebeb Gebretsadik, MD Karla Kerlikowske, PhD Virginia Ernster , MD, MPH Diana Petitti

Endometrial cancer risk increases substantially with long duration of unopposed estrogen use, and this increased risk persists for several years after discontinuation of estrogen.

Meta Analysis
1 effect
10 years

Reported Outcomes

VariablesOutcomeEffectLatency

Hormone Replacement Therapy Manufactured risk & protective factor
Hormone Repla...
Manufactured

Uterine Cancer Reproductive outcome
Uterine Cancer
Reproductive

Strong Increase

Login required to view